[Chemotherapy of unresectable Borrmann type 4 gastric cancer].
We have reported the results of our questionnaires collected from 108 hospitals all over Japan. The mainly used therapies were 5-FU, tegafur, and MMC in singular medications and 5-FU + MMC, MFC and tegafur + MMC in combined medications. The total cases judged as 'effective' in each hospitals were 71. The breakdown is as follows: 1) 'effective for the primary lesion'--47, 33--expansion of affected site proved by radiological and endoscopic views, 6--improvement only by endoscopic findings, 8--shrinkage of palpable tumor size. 2) 'ineffective for the primary lesion'--24, 11--disappearance or decrease in ascites, 13--improvement of sign and symptom. 50% survival period was 2.9 months in ineffective cases and 8.5 months in all effective cases and 10.5 months in effective cases by radiological and endoscopic findings. Draft of the Criteria of Cancer Chemotherapy for Gastric Cancers proposed by Japanese Research Society for Gastric Cancer, which including the evaluation of Borrmann type 4 cancer, was introduced.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage; D004338:Drug Combinations / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D015376:Nimustine; D009607:Nitrosourea Compounds / Q000008:administration & dosage; D010844:Picibanil / Q000008:administration & dosage; D011509:Proteoglycans / Q000008:administration & dosage; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
D004338:Drug Combinations; D008937:Mitomycins; D009607:Nitrosourea Compounds; D011509:Proteoglycans; D015376:Nimustine; D005641:Tegafur; D010844:Picibanil; C010770:polysaccharide-K; D016685:Mitomycin; D014498:Uracil; D004317:Doxorubicin; D005472:Fluorouracil